Novo Nordisk

Novo Nordisk Lifts 2026 Outlook as CFO Change and Insider Sale Muddy the Signal

Brett Shapiro -

Novo Nordisk’s Clinical Ledger: A Pediatric Insulin Approval, Exploratory Weight-Loss Data and Lilly’s Direct Challenge

Novo Nordisk’s Ozempic Slips in America as Buyback and Pipeline News Vie for Investor Attention

Brett Shapiro -

Novo Nordisk Faces US Lawsuits Over Vision Damage Claims While Racing to Defend Its GLP-1 Empire

Novo Nordisk’s Buyback Bet: Can a Paediatric Win Outweigh a Cardiology Programme Unravelling?

angelina -

Novo Nordisk Faces a September Reckoning as Oral Wegovy’s China Hopes Collide With Analyst Doubts

kashif hafeez -

Novo Nordisk’s Split Personality: Record US Scripts Versus a Pipeline That Just Won’t Cooperate

angelina -

Novo Nordisk’s Oral Wegovy Push Lands in Germany While a London Showdown Looms

kashif hafeez -

Novo Nordisk’s Krone-Sized Question: Can Buybacks Outweigh a Broken Pipeline Narrative?

Novo Nordisk’s Multi-Front Defense: Lawsuits, Buybacks, and a Split Decision on Wall Street

Novo Nordisk’s Contradictory Signals: A Downgrade, a Buyback, and a Race Against Lilly

Brett Shapiro -

Novo Nordisk’s Balancing Act: A Failed Heart Study, a Legal Win, and a Quiet Bet on Smaller Doses

Brett Shapiro -

Novo Nordisk’s Capital Discipline Meets a Market That’s Still Not Convinced

Brett Shapiro -

Novo Nordisk’s Defensive Posture: A Market Leader Fighting on Multiple Fronts

Novo Nordisk’s Confidence Gap: When Raised Guidance Isn’t Enough

kashif hafeez -
123...5Page 1 of 5